DICE Therapeutics, Inc. (DICE) Financial Statements (2026 and earlier)

Company Profile

Business Address 400 EAST JAMIE COURT
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments554,548,000574,225,000266,614,000282,221,000303,231,000319,321,000
Cash and cash equivalent101,594,000461,393,00048,271,00016,767,00053,668,000115,826,000
Short-term investments452,954,000112,832,000218,343,000265,454,000249,563,000203,495,000
Restricted cash and investments     150,000150,000
Receivables    1,500,0002,000,0002,000,000
Other undisclosed current assets4,802,0003,537,0001,223,0001,155,0001,615,0002,440,000
Total current assets:559,350,000577,762,000267,837,000284,876,000306,996,000323,911,000
Noncurrent Assets
Operating lease, right-of-use asset12,711,00013,097,00013,474,00013,844,00014,327,000 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization3,345,0002,921,0003,014,0003,109,0003,088,0001,645,000
Restricted cash and investments198,000198,000198,000198,000198,000198,000
Other noncurrent assets  471,000554,000  
Total noncurrent assets:16,254,00016,216,00017,157,00017,705,00017,613,0001,843,000
TOTAL ASSETS:575,604,000593,978,000284,994,000302,581,000324,609,000325,754,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,122,0007,368,0001,388,0001,963,0004,753,0003,950,000
Employee-related liabilities✕✕✕✕✕✕1,957,000
Accounts payable4,122,0003,075,0001,388,0001,963,0004,753,0001,710,000
Accrued liabilities  4,293,000   283,000
Debt     714,000480,000
Other undisclosed current liabilities13,119,0007,781,00010,277,00010,103,0009,327,0006,451,000
Total current liabilities:17,241,00015,149,00011,665,00012,066,00014,794,00010,881,000
Noncurrent Liabilities
Long-term debt and lease obligation   12,215,00012,580,00014,646,0001,916,000
Long-term debt, excluding current maturities     1,710,0001,916,000
Liabilities, other than long-term debt11,458,00011,841,000   8,000
Deferred rent credit      8,000
Operating lease, liability11,458,00011,841,00012,215,00012,580,00012,936,000 
Other undisclosed noncurrent liabilities   (12,215,000)(12,580,000)(12,936,000) 
Total noncurrent liabilities:11,458,00011,841,00012,215,00012,580,00014,646,0001,924,000
Total liabilities:28,699,00026,990,00023,880,00024,646,00029,440,00012,805,000
Equity
Equity, attributable to parent, including:546,905,000566,988,000261,114,000277,935,000295,169,000312,949,000
Common stock5,0005,0004,0004,000  
Additional paid in capital760,437,000755,174,000426,798,000423,333,000418,603,000416,710,000
Accumulated other comprehensive income (loss)(297,000)(597,000)(1,318,000)(1,582,000)(1,140,000)(58,000)
Accumulated deficit(213,240,000)(187,594,000)(164,370,000)(143,820,000)(122,298,000)(103,707,000)
Other undisclosed equity, attributable to parent     4,0004,000
Total equity:546,905,000566,988,000261,114,000277,935,000295,169,000312,949,000
TOTAL LIABILITIES AND EQUITY:575,604,000593,978,000284,994,000302,581,000324,609,000325,754,000

Income Statement (P&L) (USD)
Annual | Quarterly

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Operating expenses(31,575,000)(26,450,000)(21,169,000)(21,744,000)(18,858,000)(16,210,000)
Operating loss:(31,575,000)(26,450,000)(21,169,000)(21,744,000)(18,858,000)(16,210,000)
Interest and debt expense  208,000(83,000)(265,000)(60,000)(60,000)
Loss from continuing operations:(31,575,000)(26,242,000)(21,252,000)(22,009,000)(18,918,000)(16,270,000)
Loss before gain (loss) on sale of properties:✕✕✕(21,252,000)(22,009,000)(18,918,000)(16,270,000)
Net loss:(31,575,000)(26,242,000)(21,252,000)(22,009,000)(18,918,000)(16,270,000)
Other undisclosed net income attributable to parent5,929,0003,018,000702,000487,000327,00075,000
Net loss available to common stockholders, diluted:(25,646,000)(23,224,000)(20,550,000)(21,522,000)(18,591,000)(16,195,000)

Comprehensive Income (USD)
Annual | Quarterly

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Net loss:(31,575,000)(26,242,000)(21,252,000)(22,009,000)(18,918,000)(16,270,000)
Other comprehensive income (loss)300,000 264,000(442,000)(1,082,000) 
Other undisclosed comprehensive loss  (539,000)   (58,000)
Comprehensive loss:(31,275,000)(26,781,000)(20,988,000)(22,451,000)(20,000,000)(16,328,000)
Other undisclosed comprehensive income, net of tax, attributable to parent5,929,0004,278,000702,000487,000327,00077,000
Comprehensive loss, net of tax, attributable to parent:(25,346,000)(22,503,000)(20,286,000)(21,964,000)(19,673,000)(16,251,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: